GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alk-Abello AS (OCSE:ALK B) » Definitions » Cyclically Adjusted PB Ratio

Alk-Abello AS (OCSE:ALK B) Cyclically Adjusted PB Ratio : 10.35 (As of Jul. 05, 2025)


View and export this data going back to 2005. Start your Free Trial

What is Alk-Abello AS Cyclically Adjusted PB Ratio?

As of today (2025-07-05), Alk-Abello AS's current share price is kr189.80. Alk-Abello AS's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2025 was kr18.34. Alk-Abello AS's Cyclically Adjusted PB Ratio for today is 10.35.

The historical rank and industry rank for Alk-Abello AS's Cyclically Adjusted PB Ratio or its related term are showing as below:

OCSE:ALK B' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 2.65   Med: 7.14   Max: 12.11
Current: 10.11

During the past years, Alk-Abello AS's highest Cyclically Adjusted PB Ratio was 12.11. The lowest was 2.65. And the median was 7.14.

OCSE:ALK B's Cyclically Adjusted PB Ratio is ranked worse than
89.4% of 679 companies
in the Biotechnology industry
Industry Median: 1.56 vs OCSE:ALK B: 10.11

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Alk-Abello AS's adjusted book value per share data for the three months ended in Mar. 2025 was kr25.637. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is kr18.34 for the trailing ten years ended in Mar. 2025.

Shiller PE for Stocks: The True Measure of Stock Valuation


Alk-Abello AS Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Alk-Abello AS's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alk-Abello AS Cyclically Adjusted PB Ratio Chart

Alk-Abello AS Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 9.24 11.99 6.01 6.06 8.90

Alk-Abello AS Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.24 8.82 9.74 8.90 7.57

Competitive Comparison of Alk-Abello AS's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Alk-Abello AS's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alk-Abello AS's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alk-Abello AS's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Alk-Abello AS's Cyclically Adjusted PB Ratio falls into.


;
;

Alk-Abello AS Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Alk-Abello AS's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=189.80/18.34
=10.35

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alk-Abello AS's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, Alk-Abello AS's adjusted Book Value per Share data for the three months ended in Mar. 2025 was:

Adj_Book=Book Value per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=25.637/120.2000*120.2000
=25.637

Current CPI (Mar. 2025) = 120.2000.

Alk-Abello AS Quarterly Data

Book Value per Share CPI Adj_Book
201506 12.835 100.300 15.382
201509 13.074 100.200 15.684
201512 13.806 99.800 16.628
201603 14.139 100.200 16.961
201606 14.454 100.600 17.270
201609 14.434 100.200 17.315
201612 14.621 100.300 17.522
201703 14.357 101.200 17.052
201706 14.167 101.200 16.827
201709 14.001 101.800 16.532
201712 15.283 101.300 18.134
201803 15.269 101.700 18.047
201806 15.217 102.300 17.880
201809 15.041 102.400 17.656
201812 14.737 102.100 17.350
201903 15.150 102.900 17.697
201906 14.585 102.900 17.037
201909 14.664 102.900 17.129
201912 14.568 102.900 17.017
202003 15.019 103.300 17.476
202006 14.854 103.200 17.301
202009 14.671 103.500 17.038
202012 14.426 103.400 16.770
202103 15.137 104.300 17.445
202106 14.800 105.000 16.942
202109 15.094 105.800 17.148
202112 15.829 106.600 17.848
202203 16.602 109.900 18.158
202206 17.193 113.600 18.192
202209 17.869 116.400 18.452
202212 18.045 115.900 18.714
202303 18.634 117.300 19.095
202306 18.916 116.400 19.534
202309 19.626 117.400 20.094
202312 20.105 116.700 20.708
202403 21.190 118.400 21.512
202406 22.225 118.500 22.544
202409 22.973 118.900 23.224
202412 24.268 118.900 24.533
202503 25.637 120.200 25.637

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Alk-Abello AS  (OCSE:ALK B) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Alk-Abello AS Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Alk-Abello AS's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Alk-Abello AS Business Description

Industry
Traded in Other Exchanges
Address
Boge Alle 6-8, Horsholm, DNK, DK-2970
Alk-Abello AS is a biotechnology company that focuses on pharmaceutical prevention, diagnosis, and treatment of allergies. The company is focused on respiratory diseases, including allergic rhinitis and allergic asthma. Moreover, the firm specializes in venom immunotherapy for patients suffering from bee and wasp allergies. The company's treatments induce a protective immune response that provides sustained symptom relief. Its primary focus is on allergy patients whose disease is not well controlled, despite the use of symptom-relieving medication. The company operates in Europe, North America and International Markets. It derives maximum revenue from Europe.

Alk-Abello AS Headlines

No Headlines